

Clinical trials of bococizumab

TrialResults-center www.trialresultscenter.org

1 cardiovascular prevention

| Trial | Treatments | Patients | Trials design and methods |
|--|----------------------------------|--|---------------------------|
| bococizumab vs placebo | | | |
| SPIRE-1 <i>ongoing</i> [NCT01975376] n=NA follow-up: | Bococizumab versus placebo | high risk subjects who are receiving background lipid lowering therapy and have cholesterol laboratory values of LDL-C \geq 70 mg/dL (1.8 mmol/L) and $<$ 100 mg/dL (2.6 mmol/L) or non-HDL-C \geq 100 mg /dl (2.6 mmol/L) and $<$ 130 mg/dL (3.4 mmol/L). | double-blind |
| SPIRE-2 <i>ongoing</i> [NCT01975389] n=NA follow-up: | bococizumab versus Placebo | high risk subjects who are receiving background lipid lowering therapy and have cholesterol laboratory values of LDL-C \geq 100 mg/dL (2.6 mmol/L) or non-HDL-C \geq 130 mg/dL (3.4 mmol/L). | double-blind |
| SPIRE-FH <i>ongoing</i> [NCT01968980] n=NA follow-up: | - | subjects with heterozygous familial hypercholesterolemia receiving highly effective statins | double-blind US |
| SPIRE-HR <i>ongoing</i> [NCT01968954] n=NA follow-up: | Bococizumab versus Placebo | subjects with high cholesterol receiving highly effective statins | double-blind US |
| SPIRE-LDL <i>ongoing</i> [NCT01968967] n=NA follow-up: | - | subjects with high cholesterol receiving highly effective statins | double-blind US |
| SPIRE-LL <i>ongoing</i> [NCT02100514] n=NA follow-up: | - | subjects with hyperlipidemia receiving background statin therapy | double-blind US |

continued...

| Trial | Treatments | Patients | Trials design and methods |
|---|----------------------------------|----------|---------------------------|
| SPIRE-SI <i>ongoing</i> [NCT02135029] n=NA follow-up: | Bococizumab versus Placebo | - | double-blind |

More details and results :

- PCSK9 Inhibitors for cardiovascular prevention in all type of patients at <http://www.trialresultscenter.org/go-Q599>

References

SPIRE-1, 0:

ongoing trial NCT01975376

SPIRE-2, 0:

ongoing trial NCT01975389

SPIRE-FH, 0:

ongoing trial NCT01968980

SPIRE-HR, 0:

ongoing trial NCT01968954

SPIRE-LDL, 0:

ongoing trial NCT01968967

SPIRE-LL, 0:

ongoing trial NCT02100514

SPIRE-SI, 0:

ongoing trial NCT02135029

Entry terms: bococizumab,